An operating partner staring at a confirmatory diligence window rarely has a technology problem. They have a decision problem. The deal team already believes the thesis. What they do not yet know is whether the code, the data, the team and the infrastructure will support the plan they underwrote, or quietly consume the margin they promised the investment committee. Choosing the wrong tech due diligence provider for a portfolio company is not a wasted invoice. It is a report that reads well, clears the file, and misses the two or three things that later become a re-platform, a security incident, or a founder-dependency that stalls the whole integration.
This guide is written for the person with budget who has to make that call before an LOI hardens or before Day 1 planning starts. It assumes the reader already runs deals. It does not define diligence. It sets out what to actually buy, what a competent provider produces, and how a CFO or FP&A lead should judge the output when it lands.
1. Decide what the review has to inform before you scope it
The single most common scoping error is buying a “tech audit” with no named decision attached. A technology review that informs a go/no-go looks different from one that informs a purchase-price adjustment, which looks different again from one that seeds a first 100 days execution plan. Same asset, three deliverables.
Before scoping, write down the decision the report has to feed. Bain’s annual private equity report has tracked for years how value creation has shifted from financial engineering toward operational improvement, which means the technology base increasingly sits on the critical path to the return, not adjacent to it. You can see the same theme running through McKinsey’s private capital research and BCG’s work on principal investors. If technology drives the plan, the review has to produce evidence the plan can be executed, not a catalogue of what exists.
The three decisions to name
- Should we proceed, and at what price? The output is a risk register with severity and remediation cost, tied to the model.
- What breaks on Day 1 and who owns it? The output is an integration dependency map and an owner list.
- What has to be rebuilt to hit the plan? The output is a costed technical roadmap with EBITDA linkage.
The Bain findings are summarized in Bain’s Global Private Equity Report, and the operational-value shift is worth reading alongside PitchBook’s deal and value-creation data before you set scope.
2. Match the provider tier to the deal stage and clock
Not every review needs a full engagement, and paying for one at the wrong moment burns time you do not have. The practical decision is which of two products fits the current stage.
Pre-LOI check
Before you commit exclusivity, a light, fast review answers one question: is there a technical reason not to proceed to a full process? This is a screen, not a verdict. It surfaces the obvious disqualifiers, single points of failure, unlicensed dependencies, a code base one engineer understands, a security posture that would fail a customer audit. A sensible pre-LOI check is small, credits into the deeper work if the deal advances, and protects the deal team from spending confirmatory dollars on an asset with a fatal flaw. DevriX prices a technology due diligence pre-LOI check at $5K, which credits into the fuller engagement.
Confirmatory tech DD
Once exclusivity is in place and the clock is running toward close, the full review has to produce evidence a QoE-style file would respect: findings, severity, cost, owner. DevriX runs a 5-Day Tech DD at $15K sized to fit inside a confirmatory window. The point of a fixed clock is that it forces the provider to prioritize the findings that move price or risk, rather than producing a hundred-page inventory nobody reads. The discipline mirrors what strong FP&A teams already know about producing decision-grade output, a theme covered in what actually informs the decision in portfolio FP&A analytics.
3. Know what a competent report actually contains
A weak provider hands over activity: lines of code reviewed, tools scanned, interviews conducted. A strong provider hands over consequence. The distinction matters because activity clears the file and consequence changes the deal.
What every finding needs
- Evidence. The specific artifact, repository, ticket, config, or interview that supports the claim. Not “we heard that.”
- Severity. Ranked against the thesis, not against a generic best-practice checklist.
- Remediation cost and time. A number and a duration, so it can enter the model or the roadmap.
- Owner. Who inside the portfolio company or integration team is accountable for closing it.
The severity ranking is where most reports fail. A finding is only material if it threatens the return, revenue growth, margin, cash conversion, integration speed, or exit multiple. Governance research from the Harvard Law School Forum on Corporate Governance and HBR’s ongoing coverage on mergers and acquisitions both make the same operational point: integration risk that is not owned by a named person does not get closed. Ask the provider to name owners, or ask them why they cannot.
4. Judge the provider on evidence and severity, not credentials
Credentials get a provider onto the shortlist. They do not tell you whether the work will hold up in a board room. The way to test a provider before you hire one is to make them show a redacted prior deliverable and interrogate the reasoning.
Five questions that separate real providers
- Show a redacted risk register. How is severity assigned, and against what?
- How is a remediation number produced, and what is the confidence range?
- How do you handle a founder-dependency finding without derailing the deal?
- What did you classify as realized risk avoided versus a forecast future cost?
- Who writes the section a CFO reads, and can they defend it live?
That last point matters because the buyer of this report is usually financial, not technical. The report has to translate engineering reality into EBITDA and risk language a CFO and the investment committee can act on. This is the same translation problem covered in office of the CFO services in private equity and in the guidance on what to buy from a portfolio company data strategy consultant. Practitioner standards from AICPA & CIMA reinforce the same discipline on how a number is produced and who stands behind it.
5. Connect every finding to the value plan
A finding that does not touch the value creation plan is trivia. The provider’s job is to route each material item to one of a short list of commercial outcomes: revenue growth it enables or blocks, margin it protects, cash it frees or consumes, integration time it adds, management visibility it improves, or risk it removes ahead of exit. Coverage of the value-creation shift across S&P Global Market Intelligence, Preqin’s alternative assets data, and reporting in Private Equity International all point the same way: technology now sits inside the return math, not beside it.
Where the review flags reporting or data gaps, those feed directly into the reporting build that the board will expect after close. That build is its own workstream, covered in portfolio company KPI tracking that informs a board decision and in the buyer’s guidance on FP&A automation for portfolio companies. Treating a data-quality finding as a diligence footnote, rather than a Day 1 dependency, is how visibility gaps survive into the first board meeting.
6. Turn the report into a Day 1 and first 100 days plan
The report is an input, not the deliverable that creates value. The value shows up when its findings become an owned plan with dates. Every material finding should map to Day 1 (what must be true before close closes), the first 100 days (what gets remediated fast), and the hold (what enters the roadmap). This is where the discipline used to judge dashboard and analytics work transfers directly: the same “evidence, owner, decision it informs” test applies to a technology roadmap.
Reporting and regulatory context matters here too. Public filings and enforcement patterns tracked by the U.S. Securities and Exchange Commission, plus deal coverage in Buyouts and PE Hub, show how often technology and data-handling risks that were visible in diligence surface later as real cost. Provider selection is upstream of all of that.
7. A buyer’s checklist
- The decision the report must inform is written down before scoping.
- The stage-appropriate product is chosen: a pre-LOI screen or a full confirmatory review.
- Every finding carries evidence, severity ranked against the thesis, cost, and a named owner.
- Severity is defined by threat to the return, not against a generic checklist.
- The provider can show a redacted prior deliverable and defend its reasoning live.
- The section a CFO reads is written in EBITDA and risk language, not engineering language.
- Impacts are classified as realized, run-rate, forecast, enabled, or risk avoided, with forecast never dressed as realized.
- Findings map to Day 1, first 100 days, and hold, each with an owner and a date.
Implementation note and next step
The practical failure mode is timing. Teams commission the review too late to change price, or too broad to finish inside the window, or scoped without a decision so the report clears the file and changes nothing. Fix that by naming the decision first, matching the product to the stage, and demanding evidence-backed, owner-assigned findings you can drop into the model and the 100-day plan. For a deeper view of the full technology workstream across a hold, DevriX documents its approach to private equity operating support.
If a review is on your near-term calendar, before LOI or heading into confirmatory diligence, look at how the DevriX / GrowthShuttle technology due diligence practice structures the 5-Day Tech DD and the Pre-LOI Check so the output lands as a decision-grade file, not an inventory.